Blonanserin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
First Episode Schizophrenia
Conditions
First Episode Schizophrenia, Social Function, Cognition Function, Blonanserin
Trial Timeline
Jan 22, 2019 → Nov 22, 2022
NCT ID
NCT03784222About Blonanserin
Blonanserin is a approved stage product being developed by Sumitomo Pharma for First Episode Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03784222. Target conditions include First Episode Schizophrenia, Social Function, Cognition Function.
What happened to similar drugs?
2 of 6 similar drugs in First Episode Schizophrenia were approved
Approved (2) Terminated (0) Active (4)
🔄HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
🔄Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03784222 | Approved | Terminated |
Competing Products
12 competing products in First Episode Schizophrenia